search
Back to results

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Primary Purpose

Pulmonary Disease, Chronic Obstructive

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
tiotropium
placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Written informed consent. Male or female patients 40 years of age or older. Smoking history of at least 10 pack years. Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1<70% of FVC and on stable respiratory medication. Exclusion Criteria: Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate. Myocardial infarction in past 6 months. Unstable or life threatening arrhythmia in past year. Hospitalization for NYHA heart failure class III or IV in past year. Active tuberculosis. Asthma. Pulmonary resection. Malignancy treated with radiation or chemotherapy in past 5 years. Respiratory infection in 4 weeks prior to screening. Known hypersensitivity to anticholinergic drugs or components. Known moderate to severe renal impairment. Known narrow angle glaucoma. Significant symptomatic BPH or bladder neck obstruction. Need for oxygen therapy >12 hr/day. Use of oral corticosteroids at unstable doses or >10 mg/day.

Sites / Locations

  • 205.235.3779 Boehringer Ingelheim Investigational Site
  • 205.235.3785 Boehringer Ingelheim Investigational Site
  • 205.235.3804 Boehringer Ingelheim Investigational Site
  • 205.235.3795 Boehringer Ingelheim Investigational Site
  • 205.235.3759 Boehringer Ingelheim Investigational Site
  • 205.235.3770 Boehringer Ingelheim Investigational Site
  • 205.235.3778 Boehringer Ingelheim Investigational Site
  • 205.235.3810 Boehringer Ingelheim Investigational Site
  • 205.235.3758 Boehringer Ingelheim Investigational Site
  • 205.235.3812 Boehringer Ingelheim Investigational Site
  • 205.235.3773 Boehringer Ingelheim Investigational Site
  • 205.235.3800 Boehringer Ingelheim Investigational Site
  • 205.235.3802 Boehringer Ingelheim Investigational Site
  • 205.235.3786 Pulmonary and Critical Care Medicine
  • 205.235.3811 Boehringer Ingelheim Investigational Site
  • 205.235.3741 Boehringer Ingelheim Investigational Site
  • 205.235.3717 Boehringer Ingelheim Investigational Site
  • 205.235.3781 Boehringer Ingelheim Investigational Site
  • 205.235.3784 Boehringer Ingelheim Investigational Site
  • 205.235.3760 Boehringer Ingelheim Investigational Site
  • 205.235.3711 Boehringer Ingelheim Investigational Site
  • 205.235.3764 Boehringer Ingelheim Investigational Site
  • 205.235.3783 Boehringer Ingelheim Investigational Site
  • 205.235.3727 Boehringer Ingelheim Investigational Site
  • 205.235.3808 Boehringer Ingelheim Investigational Site
  • 205.235.3793 Boehringer Ingelheim Investigational Site
  • 205.235.3815 Boehringer Ingelheim Investigational Site
  • 205.235.3706 Boehringer Ingelheim Investigational Site
  • 205.235.3762 Boehringer Ingelheim Investigational Site
  • 205.235.3707 Boehringer Ingelheim Investigational Site
  • 205.235.3703 Boehringer Ingelheim Investigational Site
  • 205.235.3775 Boehringer Ingelheim Investigational Site
  • 205.235.3743 Boehringer Ingelheim Investigational Site
  • 205.235.3756 Boehringer Ingelheim Investigational Site
  • 205.235.3739 Boehringer Ingelheim Investigational Site
  • 205.235.3719 Boehringer Ingelheim Investigational Site
  • 205.235.3790 Boehringer Ingelheim Investigational Site
  • 205.235.3716 Boehringer Ingelheim Investigational Site
  • 205.235.3794 Boehringer Ingelheim Investigational Site
  • 205.235.3724 Boehringer Ingelheim Investigational Site
  • 205.235.3713 Boehringer Ingelheim Investigational Site
  • 205.235.3768 Boehringer Ingelheim Investigational Site
  • 205.235.3749 Boehringer Ingelheim Investigational Site
  • 205.235.3757 Boehringer Ingelheim Investigational Site
  • 205.235.3729 Boehringer Ingelheim Investigational Site
  • 205.235.3737 Boehringer Ingelheim Investigational Site
  • 205.235.3788 Boehringer Ingelheim Investigational Site
  • 205.235.3750 Boehringer Ingelheim Investigational Site
  • 205.235.3806 Boehringer Ingelheim Investigational Site
  • 205.235.3721 Boehringer Ingelheim Investigational Site
  • 205.235.3726 354 Birnie Ave
  • 205.235.3813 Boehringer Ingelheim Investigational Site
  • 205.235.3732 Boehringer Ingelheim Investigational Site
  • 205.235.3809 Boehringer Ingelheim Investigational Site
  • 205.235.3751 Boehringer Ingelheim Investigational Site
  • 205.235.3754 Boehringer Ingelheim Investigational Site
  • 205.235.3789 Boehringer Ingelheim Investigational Site
  • 205.235.3734 Boehringer Ingelheim Investigational Site
  • 205.235.3814 Boehringer Ingelheim Investigational Site
  • 205.235.3747 Boehringer Ingelheim Investigational Site
  • 205.235.3763 Boehringer Ingelheim Investigational Site
  • 205.235.3797 Boehringer Ingelheim Investigational Site
  • 205.235.3799 Boehringer Ingelheim Investigational Site
  • 205.235.3796 Boehringer Ingelheim Investigational Site
  • 205.235.3807 Boehringer Ingelheim Investigational Site
  • 205.235.3816 Boehringer Ingelheim Investigational Site
  • 205.235.3765 Boehringer Ingelheim Investigational Site
  • 205.235.3748 Boehringer Ingelheim Investigational Site
  • 205.235.3818 Boehringer Ingelheim Investigational Site
  • 205.235.3722 Boehringer Ingelheim Investigational Site
  • 205.235.3730 Boehringer Ingelheim Investigational Site
  • 205.235.3731 Boehringer Ingelheim Investigational Site
  • 205.235.3736 Boehringer Ingelheim Investigational Site
  • 205.235.3745 Boehringer Ingelheim Investigational Site
  • 205.235.3712 Boehringer Ingelheim Investigational Site
  • 205.235.3723 Boehringer Ingelheim Investigational Site
  • 205.235.3701 Boehringer Ingelheim Investigational Site
  • 205.235.3791 Boehringer Ingelheim Investigational Site
  • 205.235.3820 Boehringer Ingelheim Investigational Site
  • 205.235.3725 Boehringer Ingelheim Investigational Site
  • 205.235.3817 Boehringer Ingelheim Investigational Site
  • 205.235.3715 Boehringer Ingelheim Investigational Site
  • 205.235.3803 Boehringer Ingelheim Investigational Site
  • 205.235.3742 Boehringer Ingelheim Investigational Site
  • 205.235.3787 Boehringer Ingelheim Investigational Site
  • 205.235.3704 Boehringer Ingelheim Investigational Site
  • 205.235.3752 Boehringer Ingelheim Investigational Site
  • 205.235.3744 Boehringer Ingelheim Investigational Site
  • 205.235.3782 Boehringer Ingelheim Investigational Site
  • 205.235.3771 Boehringer Ingelheim Investigational Site
  • 205.235.3738 Boehringer Ingelheim Investigational Site
  • 205.235.3792 Boehringer Ingelheim Investigational Site
  • 205.235.3761 Boehringer Ingelheim Investigational Site
  • 205.235.3718 Boehringer Ingelheim Investigational Site
  • 205.235.3780 Boehringer Ingelheim Investigational Site
  • 205.235.101
  • 205.235.101 Boehringer Ingelheim Investigational Site
  • 205.235.103 Hospital Alemán
  • 205.235.104 Hospital de Clinicas José de San Martín
  • 205.235.105 Hospital General de Agudos José María Ramos Mejía
  • 205.235.107 Policlínica Bancaria
  • 205.235.108 Hospital General de Agudos Dr. Enrique Tornú
  • 205.235.109 Hospital Muñiz
  • 205.235.110 Hospital Privado - Centro Médico de Córdoba S.A.
  • 205.235.102 Instituto Cardiovascular de Rosario
  • 205.235.106 Hospital Cetrángolo
  • 205.235.0205 Boehringer Ingelheim Investigational Site
  • 205.235.0202 Boehringer Ingelheim Investigational Site
  • 205.235.0209 Boehringer Ingelheim Investigational Site
  • 205.235.0204 Boehringer Ingelheim Investigational Site
  • 205.235.0203 Boehringer Ingelheim Investigational Site
  • 205.235.0207 Boehringer Ingelheim Investigational Site
  • 205.235.0206 Boehringer Ingelheim Investigational Site
  • 205.235.0201 Boehringer Ingelheim Investigational Site
  • 205.235.0303 Boehringer Ingelheim Investigational Site
  • 205.235.0305 Boehringer Ingelheim Investigational Site
  • 205.235.0304 Boehringer Ingelheim Investigational Site
  • 205.235.0301 Boehringer Ingelheim Investigational Site
  • 205.235.0302 Boehringer Ingelheim Investigational Site
  • 205.235.0439 Boehringer Ingelheim Investigational Site
  • 205.235.0429 Boehringer Ingelheim Investigational Site
  • 205.235.0421 Boehringer Ingelheim Investigational Site
  • 205.235.0424 Boehringer Ingelheim Investigational Site
  • 205.235.0432 Boehringer Ingelheim Investigational Site
  • 205.235.0434 Boehringer Ingelheim Investigational Site
  • 205.235.0422 Boehringer Ingelheim Investigational Site
  • 205.235.0405 Boehringer Ingelheim Investigational Site
  • 205.235.0414 Boehringer Ingelheim Investigational Site
  • 205.235.0418 U.Z. Gent
  • 205.235.0417 Boehringer Ingelheim Investigational Site
  • 205.235.0402 Boehringer Ingelheim Investigational Site
  • 205.235.0409 Boehringer Ingelheim Investigational Site
  • 205.235.0407 Boehringer Ingelheim Investigational Site
  • 205.235.0440 Boehringer Ingelheim Investigational Site
  • 205.235.0403 Boehringer Ingelheim Investigational Site
  • 205.235.0406 Boehringer Ingelheim Investigational Site
  • 205.235.0404 Boehringer Ingelheim Investigational Site
  • 205.235.0438 Boehringer Ingelheim Investigational Site
  • 205.235.0437 Boehringer Ingelheim Investigational Site
  • 205.235.0420 Boehringer Ingelheim Investigational Site
  • 205.235.0435 Boehringer Ingelheim Investigational Site
  • 205.235.0423 Boehringer Ingelheim Investigational Site
  • 205.235.0433 Boehringer Ingelheim Investigational Site
  • 205.235.0412 Boehringer Ingelheim Investigational Site
  • 205.235.0413 Boehringer Ingelheim Investigational Site
  • 205.235.0428 Boehringer Ingelheim Investigational Site
  • 205.235.510 Servico de Pneumologia
  • 205.235.508
  • 205.235.501
  • 205.235.503
  • 205.235.506
  • 205.235.507 Depto.de Medicina Interna-Servico de pneumologia
  • 205.235.502
  • 205.235.505 Dep.Medicina Especializada (DEMESP)
  • 205.235.511 Departamento de Pneumologia
  • 205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar
  • 205.235.512
  • 205.235.513
  • 205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina
  • 205.235.515 Lar Escola São Francisco / Setor de Pneumologia
  • 205.235.0712 Boehringer Ingelheim Investigational Site
  • 205.235.0711 Boehringer Ingelheim Investigational Site
  • 205.235.0718 Clinic of Functional Diagnostics and Rehabilitation
  • 205.235.0725 University Hospital Brno
  • 205.235.0720 Office of Pulmonology and Respiratory Diseases
  • 205.235.0717 Pulmonary Clinic
  • 205.235.0705 Boehringer Ingelheim Investigational Site
  • 205.235.0726 Private Office of Pulmonary Diseases
  • 205.235.0722 Hospital Kromeriz
  • 205.235.0724 District Hospital Kyjov
  • 205.235.0704 Boehringer Ingelheim Investigational Site
  • 205.235.0702 Boehringer Ingelheim Investigational Site
  • 205.235.0701 Boehringer Ingelheim Investigational Site
  • 205.235.0703 Boehringer Ingelheim Investigational Site
  • 205.235.0710 Boehringer Ingelheim Investigational Site
  • 205.235.0706 Boehringer Ingelheim Investigational Site
  • 205.235.0709 Boehringer Ingelheim Investigational Site
  • 205.235.0708 Boehringer Ingelheim Investigational Site
  • 205.235.0715 Boehringer Ingelheim Investigational Site
  • 205.235.0707 Boehringer Ingelheim Investigational Site
  • 205.235.0723 Office of Pulmonary and Respiratory Diseases
  • 205.235.0721 Office of Pulmonary Diseases
  • 205.235.0713 Boehringer Ingelheim Investigational Site
  • 205.235.0714 Boehringer Ingelheim Investigational Site
  • 205.235.0719 Office of Pulmonology and Respiratory Diseases
  • 205.235.0716 Boehringer Ingelheim Investigational Site
  • 205.235.0826 Boehringer Ingelheim Investigational Site
  • 205.235.0804 Boehringer Ingelheim Investigational Site
  • 205.235.0803 Boehringer Ingelheim Investigational Site
  • 205.235.0828 Boehringer Ingelheim Investigational Site
  • 205.235.0802 Boehringer Ingelheim Investigational Site
  • 205.235.0831 Boehringer Ingelheim Investigational Site
  • 205.235.0821 Boehringer Ingelheim Investigational Site
  • 205.235.0832 Boehringer Ingelheim Investigational Site
  • 205.235.0807 Boehringer Ingelheim Investigational Site
  • 205.235.0805 Boehringer Ingelheim Investigational Site
  • 205.235.0835 Boehringer Ingelheim Investigational Site
  • 205.235.0816 Boehringer Ingelheim Investigational Site
  • 205.235.0811 Boehringer Ingelheim Investigational Site
  • 205.235.0834 Boehringer Ingelheim Investigational Site
  • 205.235.0806 Boehringer Ingelheim Investigational Site
  • 205.235.0814 Boehringer Ingelheim Investigational Site
  • 205.235.0801 Boehringer Ingelheim Investigational Site
  • 205.235.0833 Boehringer Ingelheim Investigational Site
  • 205.235.0830 Boehringer Ingelheim Investigational Site
  • 205.235.0819 Boehringer Ingelheim Investigational Site
  • 205.235.0810 Boehringer Ingelheim Investigational Site
  • 205.235.0809 Boehringer Ingelheim Investigational Site
  • 205.235.0815 Boehringer Ingelheim Investigational Site
  • 205.235.0824 Boehringer Ingelheim Investigational Site
  • 205.235.0813 Boehringer Ingelheim Investigational Site
  • 205.235.0822 Boehringer Ingelheim Investigational Site
  • 205.235.0820 Boehringer Ingelheim Investigational Site
  • 205.235.0808 Boehringer Ingelheim Investigational Site
  • 205.235.0827 Boehringer Ingelheim Investigational Site
  • 205.235.0903 Boehringer Ingelheim Investigational Site
  • 205.235.0901 Boehringer Ingelheim Investigational Site
  • 205.235.0905 Boehringer Ingelheim Investigational Site
  • 205.235.0904 Boehringer Ingelheim Investigational Site
  • 205.235.0902 Boehringer Ingelheim Investigational Site
  • 205.235.1004 Clinique Toulouse Lautrec
  • 205.235.1007 Cabinet Médical
  • 205.235.1015 Centre Hospitalier
  • 205.235.1012 Cabinet Médical
  • 205.235.1024 Cabinet Médical
  • 205.235.1006 Centre Hospitalier de Chauny
  • 205.235.1005 Polyclinique
  • 205.235.1013 Cabinet Médical
  • 205.235.1020 Cabinet Médical
  • 205.235.1023 Cabinet Médical
  • 205.235.1025 Centre Médical Erdre Saint Augustin
  • 205.235.1002 Cabinet médical
  • 205.235.1001 Hôpital Bichat
  • 205.235.1016 Cabinet Médical
  • 205.235.1019 Cabinet Médical
  • 205.235.1009 Centre Hospitalier de Bigorre
  • 205.235.1021 Clinique Pasteur
  • 205.235.1113 Boehringer Ingelheim Investigational Site
  • 205.235.1114 Boehringer Ingelheim Investigational Site
  • 205.235.1103 Boehringer Ingelheim Investigational Site
  • 205.235.1105 Boehringer Ingelheim Investigational Site
  • 205.235.1104 Boehringer Ingelheim Investigational Site
  • 205.235.1115 Boehringer Ingelheim Investigational Site
  • 205.235.1109 Boehringer Ingelheim Investigational Site
  • 205.235.1108 Boehringer Ingelheim Investigational Site
  • 205.235.1102 Boehringer Ingelheim Investigational Site
  • 205.235.1106 Boehringer Ingelheim Investigational Site
  • 205.235.1110 Boehringer Ingelheim Investigational Site
  • 205.235.1101 Boehringer Ingelheim Investigational Site
  • 205.235.1107 Boehringer Ingelheim Investigational Site
  • 205.235.1112 Boehringer Ingelheim Investigational Site
  • 205.235.1202 8th Pulmonology Clinic "Sotiria" Athens Chest Hospital
  • 205.235.1203 Boehringer Ingelheim Investigational Site
  • 205.235.1201 Boehringer Ingelheim Investigational Site
  • 205.235.1211 Boehringer Ingelheim Investigational Site
  • 205.235.1204 Boehringer Ingelheim Investigational Site
  • 205.235.1209 Boehringer Ingelheim Investigational Site
  • 205.235.1210 Boehringer Ingelheim Investigational Site
  • 205.235.1205 Boehringer Ingelheim Investigational Site
  • 205.235.1206 Boehringer Ingelheim Investigational Site
  • 205.235.1207 Boehringer Ingelheim Investigational Site
  • 205.235.1401 Boehringer Ingelheim Investigational Site
  • 205.235.1403 Boehringer Ingelheim Investigational Site
  • 205.235.1402 Boehringer Ingelheim Investigational Site
  • 205.235.1404 Boehringer Ingelheim Investigational Site
  • 205.235.1303 Boehringer Ingelheim Investigational Site
  • 205.235.1308 Boehringer Ingelheim Investigational Site
  • 205.235.1309 Boehringer Ingelheim Investigational Site
  • 205.235.1310 Boehringer Ingelheim Investigational Site
  • 205.235.1311 Boehringer Ingelheim Investigational Site
  • 205.235.1318 Boehringer Ingelheim Investigational Site
  • 205.235.1314 Boehringer Ingelheim Investigational Site
  • 205.235.1306 Boehringer Ingelheim Investigational Site
  • 205.235.1315 Boehringer Ingelheim Investigational Site
  • 205.235.1320 Boehringer Ingelheim Investigational Site
  • 205.235.1307 Boehringer Ingelheim Investigational Site
  • 205.235.1304 Boehringer Ingelheim Investigational Site
  • 205.235.1317 Boehringer Ingelheim Investigational Site
  • 205.235.1301 Boehringer Ingelheim Investigational Site
  • 205.235.1313 Boehringer Ingelheim Investigational Site
  • 205.235.1305 Boehringer Ingelheim Investigational Site
  • 205.235.1319 Boehringer Ingelheim Investigational Site
  • 205.235.1302 Boehringer Ingelheim Investigational Site
  • 205.235.1316 Boehringer Ingelheim Investigational Site
  • 205.235.1312 Boehringer Ingelheim Investigational Site
  • 205.235.1505 Boehringer Ingelheim Investigational Site
  • 205.235.1503 Boehringer Ingelheim Investigational Site
  • 205.235.1501 Boehringer Ingelheim Investigational Site
  • 205.235.1631 A. O. SS. Antonio e Biagio e Arrigo
  • 205.235.1613 A. O. S. Giuseppe Moscati
  • 205.235.1618 Ospedale Bellaria
  • 205.235.1649 Ospedale di Circolo di Busto Arsizio
  • 205.235.1635 P. O. Roberto Binaghi
  • 205.235.1623 A. O. di Carrara
  • 205.235.1645 Ospedale Civile "Zappatoni"
  • 205.235.1617 Ospedale S. Camillo De Lellis
  • 205.235.1612 A. O. S. Antonio Abate
  • 205.235.1622 A. O. S. Anna
  • 205.235.1646 A. O. di Careggi
  • 205.235.1647 A. O. Careggi
  • 205.235.1615 Ospedale S. Martino
  • 205.235.1603 P. O. di Gubbio
  • 205.235.1619 A. O. Fratelli Crobu
  • 205.235.1648 Ospedale "S. Maria di Collemaggio"
  • 205.235.1624 Ospedale di Macerata
  • 205.235.1634 P. O. Luigi Sacco
  • 205.235.1639 Ospedale Maggiore
  • 205.235.1629 A. O. S. Luigi Gonzaga
  • 205.235.1604 P. O. R. Silvestrini
  • 205.235.1601 Presidio Ospedaliero di Cisanello
  • 205.235.1643 A. O. Santa Maria degli Angeli
  • 205.235.1614 Ospedale Misericordia e Dolce
  • 205.235.1607 Università degli Studi di Sassari
  • 205.235.1608 ASL 1 di Sassari
  • 205.235.1606 ASL 4 di Terni
  • 205.235.1632 ASL 4 - Distretto 2
  • 205.235.1633 A. O. Umberto I
  • 205.235.1640 P. O. Cà Foncello
  • 205.235.1602 Ospedale di Voghera
  • 205.235.1706 Juntendo University Hospital
  • 205.235.1705 Kameda Medical Center
  • 205.235.1713 Komaki City Hospital
  • 205.235.1712 Kurume University Hospital
  • 205.235.1708 Shinshu University
  • 205.235.1702 Iwate Medical University Hospital
  • 205.235.1710 Osaka City University Hospital
  • 205.235.1711 Kinki University Hospital
  • 205.235.1701 Hokkaido University
  • 205.235.1703 Tohoku University Hospital
  • 205.235.1709 Tosei General Hospital
  • 205.235.1704 Hiraka General Hospital
  • 205.235.1801 Boehringer Ingelheim Investigational Site
  • 205.235.1802 Boehringer Ingelheim Investigational Site
  • 205.235.1803 Boehringer Ingelheim Investigational Site
  • 205.235.1901 Boehringer Ingelheim Investigational Site
  • 205.235.1902 Boehringer Ingelheim Investigational Site
  • 205.235.1903 Boehringer Ingelheim Investigational Site
  • 205.235.2005
  • 205.235.2006 Tlalpan 4000, Pabellón 5, EPOC
  • 205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B.
  • 205.235.2002
  • 205.235.2009
  • 205.235.2010 Depto. De Ivestigación
  • 205.235.2003
  • 205.235.2110 Poli Longziekten
  • 205.235.2105 Lokatie De Lichtenberg
  • 205.235.2107 Poli Longziekten
  • 205.235.2106 Lokatie Dordwijk
  • 205.235.2104 Poli longziekten
  • 205.235.2102 Martini Ziekenhuis Groningen
  • 205.235.2112 Poli Longziekten
  • 205.235.2115 Poli Longziekten
  • 205.235.2101 Atrium medisch centrum
  • 205.235.2114 Poli Longziekten
  • 205.235.2108 Poli Longziekten
  • 205.235.2109 Poli Longziekten
  • 205.235.2111 Antonius Ziekenhuis
  • 205.235.0211 Boehringer Ingelheim Investigational Site
  • 205.235.0212 Boehringer Ingelheim Investigational Site
  • 205.235.2202 Boehringer Ingelheim Investigational Site
  • 205.235.2201 Boehringer Ingelheim Investigational Site
  • 205.235.2205 Boehringer Ingelheim Investigational Site
  • 205.235.2204 Boehringer Ingelheim Investigational Site
  • 205.235.2301 Philippine General Hospital
  • 205.235.2305 University of Santo Tomas Hospital
  • 205.235.2302 Philippine Heart Center
  • 205.235.2303 Veterans Memorial Medical Center
  • 205.235.2304 Lung Center of the Philippines
  • 205.235.2410 Boehringer Ingelheim Investigational Site
  • 205.235.2407 Boehringer Ingelheim Investigational Site
  • 205.235.2408 Boehringer Ingelheim Investigational Site
  • 205.235.2405 Boehringer Ingelheim Investigational Site
  • 205.235.2409 Boehringer Ingelheim Investigational Site
  • 205.235.2401 Boehringer Ingelheim Investigational Site
  • 205.235.2402 Boehringer Ingelheim Investigational Site
  • 205.235.2403 Boehringer Ingelheim Investigational Site
  • 205.235.2404 Boehringer Ingelheim Investigational Site
  • 205.235.2406 Boehringer Ingelheim Investigational Site
  • 205.235.2504 Centro Hospitalar de Coimbra
  • 205.235.2503 Hospital Pulido Valente
  • 205.235.2505 Hospital de Santa Marta
  • 205.235.2501 Hospital de São João
  • 205.235.2502 Centro Hospitalar de Vila Nova de Gaia
  • 205.235.2601 Boehringer Ingelheim Investigational Site
  • 205.235.2602 Boehringer Ingelheim Investigational Site
  • 205.235.2603 Boehringer Ingelheim Investigational Site
  • 205.235.2605 Boehringer Ingelheim Investigational Site
  • 205.235.2604 Boehringer Ingelheim Investigational Site
  • 205.235.1904 Boehringer Ingelheim Investigational Site
  • 205.235.1905 Boehringer Ingelheim Investigational Site
  • 205.235.1906 Boehringer Ingelheim Investigational Site
  • 205.235.2701 Boehringer Ingelheim Investigational Site
  • 205.235.2702 Boehringer Ingelheim Investigational Site
  • 205.235.2703 Boehringer Ingelheim Investigational Site
  • 205.235.2704 Boehringer Ingelheim Investigational Site
  • 205.235.2705 Boehringer Ingelheim Investigational Site
  • 205.235.2801 Boehringer Ingelheim Investigational Site
  • 205.235.2802 Boehringer Ingelheim Investigational Site
  • 205.235.2805 Boehringer Ingelheim Investigational Site
  • 205.235.2803 Boehringer Ingelheim Investigational Site
  • 205.235.2804 Boehringer Ingelheim Investigational Site
  • 205.235.2908
  • 205.235.2910
  • 205.235.2912
  • 205.235.2904
  • 205.235.2911
  • 205.235.2902
  • 205.235.2905
  • 205.235.2901 Boehringer Ingelheim Investigational Site
  • 205.235.2906
  • 205.235.2903
  • 205.235.2909
  • 205.235.3014 Complejo Hospitalario Juan Canalejo
  • 205.235.3026 Hospital General Universitario de Alicante
  • 205.235.3011 Complejo Hospitalario Infanta Cristina
  • 205.235.3006 Hospital Germans Trias i Pujol
  • 205.235.3022 Hospital de Cruces
  • 205.235.3003 Hospital Clínic i Provincial de Barcelona
  • 205.235.3008 Hospital Vall d'Hebrón
  • 205.235.3023 Hospital Dr. Josep Trueta
  • 205.235.3004 Hospital General Universitario de Guadalajara
  • 205.235.3005 Hospital General San Jorge de Huesca
  • 205.235.3021 Hospital de Jerez de la Frontera
  • 205.235.3010 Hospital Severo Ochoa
  • 205.235.3009 Hospital Clínico San Carlos
  • 205.235.3013 Clínica Puerta de Hierro
  • 205.235.3017 Hospital Ramón y Cajal
  • 205.235.3020 Hospital Universitario La Paz
  • 205.235.3028 Hospital Universitario de la Princesa
  • 205.235.3031 Hospital Gregorio Marañón
  • 205.235.3036 Hospital 12 de Octubre
  • 205.235.3033 Hospital General Carlos Haya
  • 205.235.3027 Complejo Asistencial Son Dureta
  • 205.235.3024 Hospital de Montecelo
  • 205.235.3016 Hospital Universitari de Sant Joan
  • 205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell
  • 205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria
  • 205.235.3039 Hospital Universitario Marqués de Valdecilla
  • 205.235.3019 Hospital Vírgen de la Macarena
  • 205.235.3035 Hospital Universitario Vírgen del Rocío
  • 205.235.3001 Hospital Mutua Terrassa
  • 205.235.3002 Hospital Clínico Universitario de Valencia
  • 205.235.3025 Hospital Universitario Dr. Peset
  • 205.235.3032 Hospital Arnau de Vilanova
  • 205.235.3034 Hospital La Fe
  • 205.235.3018 Complejo Hospitalario Xeral - Cíes
  • 205.235.3030 Hospital Miguel Servet
  • 205.235.3038 Hospital Clínico Lozano Blesa
  • 205.235.3202 Boehringer Ingelheim Investigational Site
  • 205.235.3203 Universitätsspital Basel
  • 205.235.3204 Boehringer Ingelheim Investigational Site
  • 205.235.3205 Boehringer Ingelheim Investigational Site
  • 205.235.3206 Boehringer Ingelheim Investigational Site
  • 205.235.3208 Boehringer Ingelheim Investigational Site
  • 205.235.3201 Boehringer Ingelheim Investigational Site
  • 205.235.3301 Boehringer Ingelheim Investigational Site
  • 205.235.3302 Boehringer Ingelheim Investigational Site
  • 205.235.3303 Boehringer Ingelheim Investigational Site
  • 205.235.3402 Boehringer Ingelheim Investigational Site
  • 205.235.3403 Boehringer Ingelheim Investigational Site
  • 205.235.3404 Boehringer Ingelheim Investigational Site
  • 205.235.3401 Boehringer Ingelheim Investigational Site
  • 205.235.3405 Boehringer Ingelheim Investigational Site
  • 205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi
  • 205.235.3506 Hacettepe Tip Fakultesi
  • 205.235.3507 Ankara SSK Diskapi Egitim Hastanesi
  • 205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi
  • 205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye
  • 205.235.3511 Osmangazi Universitesi Tip Fakültesi
  • 205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi
  • 205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi
  • 205.235.3503 Tophanelioglu Cad. No: 13/15
  • 205.235.3504 Cevizli E5 Karayolu
  • 205.235.3505 Istanbul Universitesi Tip Fakültesi
  • 205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD
  • 205.235.3615 Boehringer Ingelheim Investigational Site
  • 205.235.3611 Boehringer Ingelheim Investigational Site
  • 205.235.3613 Boehringer Ingelheim Investigational Site
  • 205.235.3608 Boehringer Ingelheim Investigational Site
  • 205.235.3605 Boehringer Ingelheim Investigational Site
  • 205.235.3602 Boehringer Ingelheim Investigational Site
  • 205.235.3610 Boehringer Ingelheim Investigational Site
  • 205.235.3607 Boehringer Ingelheim Investigational Site
  • 205.235.3604 Boehringer Ingelheim Investigational Site
  • 205.235.3612 Boehringer Ingelheim Investigational Site
  • 205.235.3616 Boehringer Ingelheim Investigational Site
  • 205.235.3614 Boehringer Ingelheim Investigational Site
  • 205.235.3603 Boehringer Ingelheim Investigational Site
  • 205.235.3609 Boehringer Ingelheim Investigational Site
  • 205.235.3601 Boehringer Ingelheim Investigational Site

Outcomes

Primary Outcome Measures

Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.

Secondary Outcome Measures

Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1
Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1
Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score
SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).
Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Time to First Exacerbation
Chronic obstructive pulmonary disease (COPD) exacerbation
Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year
Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Number of Exacerbation Days Per Patient Year
Number of exacerbation days normalized by treatment exposure
Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)
Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization
Number of Exacerbation Leading to Hospitalization
Estimated number of exacerbations leading to hospitalizations per patient year
Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization
Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1
Estimated FEV1 before bronchodilator at Month 1
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1
Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6
Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42
Estimated FEV1 after bronchodilator at Month 42
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)
On-treatment defined as day 1 to completion of double blinded treatment plus 30 days
Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)
All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.
Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)
The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days
Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)
The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used

Full Information

First Posted
September 2, 2005
Last Updated
May 15, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00144339
Brief Title
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Official Title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
December 2002 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease, Chronic Obstructive

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Enrollment
5993 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
tiotropium
Intervention Type
Drug
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
Description
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
Time Frame
From day 30 to 4 years
Title
Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
Description
Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
Time Frame
From day 30 to 4 years
Secondary Outcome Measure Information:
Title
Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Description
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1
Time Frame
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
Title
Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Description
Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1
Time Frame
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
Title
Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
Description
Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Time Frame
From day 30 to 4 years
Title
Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
Description
Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Time Frame
From day 30 to 4 years
Title
Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
Description
Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Time Frame
From day 30 to 4 years
Title
Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
Description
Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Time Frame
From day 30 to 4 years
Title
Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score
Description
SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).
Time Frame
From month 6 to 4 years
Title
Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Description
Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Time Frame
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
Title
Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Description
Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC
Time Frame
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
Title
Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Description
Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Time Frame
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
Title
Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Description
Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC
Time Frame
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
Title
Time to First Exacerbation
Description
Chronic obstructive pulmonary disease (COPD) exacerbation
Time Frame
From Day 1 to 4 years
Title
Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year
Time Frame
Day 1 to 4 years
Title
Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Time Frame
Day 1 to 4 years
Title
Number of Exacerbation Days Per Patient Year
Description
Number of exacerbation days normalized by treatment exposure
Time Frame
Day 1 to 4 years
Title
Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)
Time Frame
Day 1 to 4 years
Title
Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization
Time Frame
From Day 1 to 4 years
Title
Number of Exacerbation Leading to Hospitalization
Description
Estimated number of exacerbations leading to hospitalizations per patient year
Time Frame
From Day 1 to 4 years
Title
Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization
Description
Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)
Time Frame
From Day 1 to 4 years
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1
Description
Estimated FEV1 before bronchodilator at Month 1
Time Frame
Month 1
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1
Description
Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1
Time Frame
Month 1
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6
Description
Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6
Time Frame
Month 6
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6
Time Frame
Month 6
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12
Time Frame
Month 12
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12
Time Frame
Month 12
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18
Time Frame
Month 18
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18
Time Frame
Month 18
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24
Time Frame
Month 24
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24
Time Frame
Month 24
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30
Time Frame
Month 30
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30
Time Frame
Month 30
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36
Time Frame
Month 36
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36
Time Frame
Month 36
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42
Time Frame
Month 42
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42
Description
Estimated FEV1 after bronchodilator at Month 42
Time Frame
Month 42
Title
Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48
Time Frame
Month 48
Title
Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48
Time Frame
Month 48
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1
Time Frame
Month 1
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1
Time Frame
Month 1
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6
Time Frame
Month 6
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6
Time Frame
Month 6
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12
Time Frame
Month 12
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12
Time Frame
Month 12
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18
Time Frame
Month 18
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18
Time Frame
Month 18
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24
Time Frame
Month 24
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24
Time Frame
Month 24
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30
Time Frame
Month 30
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30
Time Frame
Month 30
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36
Time Frame
Month 36
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36
Time Frame
Month 36
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42
Time Frame
Month 42
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42
Time Frame
Month 42
Title
Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48
Time Frame
Month 48
Title
Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48
Time Frame
Month 48
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1
Time Frame
Month 1
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1
Time Frame
Month 1
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6
Time Frame
Month 6
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6
Time Frame
Month 6
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12
Time Frame
Month 12
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12
Time Frame
Month 12
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18
Time Frame
Month 18
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18
Time Frame
Month 18
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24
Time Frame
Month 24
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24
Time Frame
Month 24
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30
Time Frame
Month 30
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30
Time Frame
Month 30
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36
Time Frame
Month 36
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36
Time Frame
Month 36
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42
Time Frame
Month 42
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42
Time Frame
Month 42
Title
Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48
Time Frame
Month 48
Title
Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48
Time Frame
Month 48
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 6
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 12
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 18
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 24
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 30
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 36
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 42
Title
Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48
Description
SGRQ total score summarizes the impact of COPD on overall patient's health status. Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. The scale is continuous. Rate of decline shows the yearly change of SGRQ total score.
Time Frame
Month 48
Title
Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)
Description
On-treatment defined as day 1 to completion of double blinded treatment plus 30 days
Time Frame
Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days
Title
Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)
Description
All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.
Time Frame
Day 1 to day 1470
Title
Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)
Description
The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days
Time Frame
Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days
Title
Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)
Description
The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used
Time Frame
Day 1 to day 1470
Other Pre-specified Outcome Measures:
Title
Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Angina)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure Congestive)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Coronary Artery Disease)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Myocardial Infarction)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (System Organ Class = Lower Respiratory System Disorders)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Bronchitis)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Chronic Obstructive Pulmonary Disease (COPD) Exacerbation)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Dyspnoea)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Pneumonia)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days
Title
Incidence Rate of Serious Adverse Event (Preferred Term = Respiratory Failure)
Description
Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.
Time Frame
Day 1 to completion of double blinded treatment plus 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent. Male or female patients 40 years of age or older. Smoking history of at least 10 pack years. Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1<70% of FVC and on stable respiratory medication. Exclusion Criteria: Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate. Myocardial infarction in past 6 months. Unstable or life threatening arrhythmia in past year. Hospitalization for NYHA heart failure class III or IV in past year. Active tuberculosis. Asthma. Pulmonary resection. Malignancy treated with radiation or chemotherapy in past 5 years. Respiratory infection in 4 weeks prior to screening. Known hypersensitivity to anticholinergic drugs or components. Known moderate to severe renal impairment. Known narrow angle glaucoma. Significant symptomatic BPH or bladder neck obstruction. Need for oxygen therapy >12 hr/day. Use of oral corticosteroids at unstable doses or >10 mg/day.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
205.235.3779 Boehringer Ingelheim Investigational Site
City
Anniston
State/Province
Alabama
Country
United States
Facility Name
205.235.3785 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
205.235.3804 Boehringer Ingelheim Investigational Site
City
Jasper
State/Province
Alabama
Country
United States
Facility Name
205.235.3795 Boehringer Ingelheim Investigational Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
205.235.3759 Boehringer Ingelheim Investigational Site
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
205.235.3770 Boehringer Ingelheim Investigational Site
City
Carmichael
State/Province
California
Country
United States
Facility Name
205.235.3778 Boehringer Ingelheim Investigational Site
City
Escondito
State/Province
California
Country
United States
Facility Name
205.235.3810 Boehringer Ingelheim Investigational Site
City
Lakewood
State/Province
California
Country
United States
Facility Name
205.235.3758 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
205.235.3812 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
205.235.3773 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
205.235.3800 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
205.235.3802 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
205.235.3786 Pulmonary and Critical Care Medicine
City
Orange
State/Province
California
Country
United States
Facility Name
205.235.3811 Boehringer Ingelheim Investigational Site
City
Palo Alto
State/Province
California
Country
United States
Facility Name
205.235.3741 Boehringer Ingelheim Investigational Site
City
Rancho Mirage
State/Province
California
Country
United States
Facility Name
205.235.3717 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
205.235.3781 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
205.235.3784 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
205.235.3760 Boehringer Ingelheim Investigational Site
City
Sepulveda
State/Province
California
Country
United States
Facility Name
205.235.3711 Boehringer Ingelheim Investigational Site
City
Stockton
State/Province
California
Country
United States
Facility Name
205.235.3764 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
205.235.3783 Boehringer Ingelheim Investigational Site
City
Wheat Ridge
State/Province
Colorado
Country
United States
Facility Name
205.235.3727 Boehringer Ingelheim Investigational Site
City
Hartford
State/Province
Connecticut
Country
United States
Facility Name
205.235.3808 Boehringer Ingelheim Investigational Site
City
Hartford
State/Province
Connecticut
Country
United States
Facility Name
205.235.3793 Boehringer Ingelheim Investigational Site
City
Norwalk
State/Province
Connecticut
Country
United States
Facility Name
205.235.3815 Boehringer Ingelheim Investigational Site
City
WEst Haven
State/Province
Connecticut
Country
United States
Facility Name
205.235.3706 Boehringer Ingelheim Investigational Site
City
Bay Pines
State/Province
Florida
Country
United States
Facility Name
205.235.3762 Boehringer Ingelheim Investigational Site
City
Brandon
State/Province
Florida
Country
United States
Facility Name
205.235.3707 Boehringer Ingelheim Investigational Site
City
Largo
State/Province
Florida
Country
United States
Facility Name
205.235.3703 Boehringer Ingelheim Investigational Site
City
Melbourne
State/Province
Florida
Country
United States
Facility Name
205.235.3775 Boehringer Ingelheim Investigational Site
City
Panama City
State/Province
Florida
Country
United States
Facility Name
205.235.3743 Boehringer Ingelheim Investigational Site
City
Sarasota
State/Province
Florida
Country
United States
Facility Name
205.235.3756 Boehringer Ingelheim Investigational Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
205.235.3739 Boehringer Ingelheim Investigational Site
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
205.235.3719 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
205.235.3790 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
205.235.3716 Boehringer Ingelheim Investigational Site
City
Augusta
State/Province
Georgia
Country
United States
Facility Name
205.235.3794 Boehringer Ingelheim Investigational Site
City
Stockbridge
State/Province
Georgia
Country
United States
Facility Name
205.235.3724 Boehringer Ingelheim Investigational Site
City
Coeur d'Alene
State/Province
Idaho
Country
United States
Facility Name
205.235.3713 Boehringer Ingelheim Investigational Site
City
Normal
State/Province
Illinois
Country
United States
Facility Name
205.235.3768 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
205.235.3749 Boehringer Ingelheim Investigational Site
City
Dubuque
State/Province
Iowa
Country
United States
Facility Name
205.235.3757 Boehringer Ingelheim Investigational Site
City
Olathe
State/Province
Kansas
Country
United States
Facility Name
205.235.3729 Boehringer Ingelheim Investigational Site
City
Lexington
State/Province
Kentucky
Country
United States
Facility Name
205.235.3737 Boehringer Ingelheim Investigational Site
City
Metairie
State/Province
Louisiana
Country
United States
Facility Name
205.235.3788 Boehringer Ingelheim Investigational Site
City
Shreveport
State/Province
Louisiana
Country
United States
Facility Name
205.235.3750 Boehringer Ingelheim Investigational Site
City
Bidderford
State/Province
Maine
Country
United States
Facility Name
205.235.3806 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
205.235.3721 Boehringer Ingelheim Investigational Site
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
205.235.3726 354 Birnie Ave
City
Springfield
State/Province
Massachusetts
Country
United States
Facility Name
205.235.3813 Boehringer Ingelheim Investigational Site
City
Ann Arbor
State/Province
Michigan
Country
United States
Facility Name
205.235.3732 Boehringer Ingelheim Investigational Site
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
205.235.3809 Boehringer Ingelheim Investigational Site
City
Livonia
State/Province
Michigan
Country
United States
Facility Name
205.235.3751 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
205.235.3754 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
205.235.3789 Boehringer Ingelheim Investigational Site
City
Rochester
State/Province
Minnesota
Country
United States
Facility Name
205.235.3734 Boehringer Ingelheim Investigational Site
City
Chesterfield
State/Province
Missouri
Country
United States
Facility Name
205.235.3814 Boehringer Ingelheim Investigational Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
205.235.3747 Boehringer Ingelheim Investigational Site
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
205.235.3763 Boehringer Ingelheim Investigational Site
City
Lebanon
State/Province
New Hampshire
Country
United States
Facility Name
205.235.3797 Boehringer Ingelheim Investigational Site
City
Cherry Hill
State/Province
New Jersey
Country
United States
Facility Name
205.235.3799 Boehringer Ingelheim Investigational Site
City
Summit
State/Province
New Jersey
Country
United States
Facility Name
205.235.3796 Boehringer Ingelheim Investigational Site
City
Albany
State/Province
New York
Country
United States
Facility Name
205.235.3807 Boehringer Ingelheim Investigational Site
City
Bayshore
State/Province
New York
Country
United States
Facility Name
205.235.3816 Boehringer Ingelheim Investigational Site
City
Bronx
State/Province
New York
Country
United States
Facility Name
205.235.3765 Boehringer Ingelheim Investigational Site
City
Larchmont
State/Province
New York
Country
United States
Facility Name
205.235.3748 Boehringer Ingelheim Investigational Site
City
Mineola
State/Province
New York
Country
United States
Facility Name
205.235.3818 Boehringer Ingelheim Investigational Site
City
New York
State/Province
New York
Country
United States
Facility Name
205.235.3722 Boehringer Ingelheim Investigational Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
205.235.3730 Boehringer Ingelheim Investigational Site
City
Burlington
State/Province
North Carolina
Country
United States
Facility Name
205.235.3731 Boehringer Ingelheim Investigational Site
City
Chapel Hill
State/Province
North Carolina
Country
United States
Facility Name
205.235.3736 Boehringer Ingelheim Investigational Site
City
Durham
State/Province
North Carolina
Country
United States
Facility Name
205.235.3745 Boehringer Ingelheim Investigational Site
City
Elizabath City
State/Province
North Carolina
Country
United States
Facility Name
205.235.3712 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
205.235.3723 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
205.235.3701 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
205.235.3791 Boehringer Ingelheim Investigational Site
City
Tulsa
State/Province
Oklahoma
Country
United States
Facility Name
205.235.3820 Boehringer Ingelheim Investigational Site
City
Portland
State/Province
Oregon
Country
United States
Facility Name
205.235.3725 Boehringer Ingelheim Investigational Site
City
Hershey
State/Province
Pennsylvania
Country
United States
Facility Name
205.235.3817 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
205.235.3715 Boehringer Ingelheim Investigational Site
City
Providence
State/Province
Rhode Island
Country
United States
Facility Name
205.235.3803 Boehringer Ingelheim Investigational Site
City
El Paso
State/Province
Texas
Country
United States
Facility Name
205.235.3742 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
205.235.3787 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
205.235.3704 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
205.235.3752 Boehringer Ingelheim Investigational Site
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
205.235.3744 Boehringer Ingelheim Investigational Site
City
Danville
State/Province
Virginia
Country
United States
Facility Name
205.235.3782 Boehringer Ingelheim Investigational Site
City
Fredericksburg
State/Province
Virginia
Country
United States
Facility Name
205.235.3771 Boehringer Ingelheim Investigational Site
City
Lynchburg
State/Province
Virginia
Country
United States
Facility Name
205.235.3738 Boehringer Ingelheim Investigational Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
205.235.3792 Boehringer Ingelheim Investigational Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
205.235.3761 Boehringer Ingelheim Investigational Site
City
Salem
State/Province
Virginia
Country
United States
Facility Name
205.235.3718 Boehringer Ingelheim Investigational Site
City
Spokane
State/Province
Washington
Country
United States
Facility Name
205.235.3780 Boehringer Ingelheim Investigational Site
City
La Crosse
State/Province
Wisconsin
Country
United States
Facility Name
205.235.101
City
Buenos Aires
Country
Argentina
Facility Name
205.235.101 Boehringer Ingelheim Investigational Site
City
Capital Federal
Country
Argentina
Facility Name
205.235.103 Hospital Alemán
City
Capital Federal
Country
Argentina
Facility Name
205.235.104 Hospital de Clinicas José de San Martín
City
Capital Federal
Country
Argentina
Facility Name
205.235.105 Hospital General de Agudos José María Ramos Mejía
City
Capital Federal
Country
Argentina
Facility Name
205.235.107 Policlínica Bancaria
City
Capital Federal
Country
Argentina
Facility Name
205.235.108 Hospital General de Agudos Dr. Enrique Tornú
City
Capital Federal
Country
Argentina
Facility Name
205.235.109 Hospital Muñiz
City
Capital Federal
Country
Argentina
Facility Name
205.235.110 Hospital Privado - Centro Médico de Córdoba S.A.
City
Parque Velez Sarlfield
Country
Argentina
Facility Name
205.235.102 Instituto Cardiovascular de Rosario
City
Rosario
Country
Argentina
Facility Name
205.235.106 Hospital Cetrángolo
City
Vicente López
Country
Argentina
Facility Name
205.235.0205 Boehringer Ingelheim Investigational Site
City
Bankstown
State/Province
New South Wales
Country
Australia
Facility Name
205.235.0202 Boehringer Ingelheim Investigational Site
City
Concord
State/Province
New South Wales
Country
Australia
Facility Name
205.235.0209 Boehringer Ingelheim Investigational Site
City
Westmead
State/Province
New South Wales
Country
Australia
Facility Name
205.235.0204 Boehringer Ingelheim Investigational Site
City
Cairns
State/Province
Queensland
Country
Australia
Facility Name
205.235.0203 Boehringer Ingelheim Investigational Site
City
Redcliffe
State/Province
Queensland
Country
Australia
Facility Name
205.235.0207 Boehringer Ingelheim Investigational Site
City
Port Lincoln
State/Province
South Australia
Country
Australia
Facility Name
205.235.0206 Boehringer Ingelheim Investigational Site
City
Box Hill
State/Province
Victoria
Country
Australia
Facility Name
205.235.0201 Boehringer Ingelheim Investigational Site
City
Geelong
State/Province
Victoria
Country
Australia
Facility Name
205.235.0303 Boehringer Ingelheim Investigational Site
City
Graz
Country
Austria
Facility Name
205.235.0305 Boehringer Ingelheim Investigational Site
City
Innsbruck
Country
Austria
Facility Name
205.235.0304 Boehringer Ingelheim Investigational Site
City
Leoben
Country
Austria
Facility Name
205.235.0301 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
205.235.0302 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
205.235.0439 Boehringer Ingelheim Investigational Site
City
Anderlecht
Country
Belgium
Facility Name
205.235.0429 Boehringer Ingelheim Investigational Site
City
Baudour
Country
Belgium
Facility Name
205.235.0421 Boehringer Ingelheim Investigational Site
City
Brugge
Country
Belgium
Facility Name
205.235.0424 Boehringer Ingelheim Investigational Site
City
Brussel
Country
Belgium
Facility Name
205.235.0432 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
205.235.0434 Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
205.235.0422 Boehringer Ingelheim Investigational Site
City
Dendermonde
Country
Belgium
Facility Name
205.235.0405 Boehringer Ingelheim Investigational Site
City
Edegem
Country
Belgium
Facility Name
205.235.0414 Boehringer Ingelheim Investigational Site
City
Gent
Country
Belgium
Facility Name
205.235.0418 U.Z. Gent
City
Gent
Country
Belgium
Facility Name
205.235.0417 Boehringer Ingelheim Investigational Site
City
Herentals
Country
Belgium
Facility Name
205.235.0402 Boehringer Ingelheim Investigational Site
City
Ieper
Country
Belgium
Facility Name
205.235.0409 Boehringer Ingelheim Investigational Site
City
Kortrijk
Country
Belgium
Facility Name
205.235.0407 Boehringer Ingelheim Investigational Site
City
Leuven
Country
Belgium
Facility Name
205.235.0440 Boehringer Ingelheim Investigational Site
City
Luxembourg
Country
Belgium
Facility Name
205.235.0403 Boehringer Ingelheim Investigational Site
City
Menen
Country
Belgium
Facility Name
205.235.0406 Boehringer Ingelheim Investigational Site
City
Merksem
Country
Belgium
Facility Name
205.235.0404 Boehringer Ingelheim Investigational Site
City
Middelheim
Country
Belgium
Facility Name
205.235.0438 Boehringer Ingelheim Investigational Site
City
Mons
Country
Belgium
Facility Name
205.235.0437 Boehringer Ingelheim Investigational Site
City
Namur
Country
Belgium
Facility Name
205.235.0420 Boehringer Ingelheim Investigational Site
City
Neerpelt
Country
Belgium
Facility Name
205.235.0435 Boehringer Ingelheim Investigational Site
City
Nobressart (ATTERT)
Country
Belgium
Facility Name
205.235.0423 Boehringer Ingelheim Investigational Site
City
Oostende
Country
Belgium
Facility Name
205.235.0433 Boehringer Ingelheim Investigational Site
City
Tournai
Country
Belgium
Facility Name
205.235.0412 Boehringer Ingelheim Investigational Site
City
Turnhout
Country
Belgium
Facility Name
205.235.0413 Boehringer Ingelheim Investigational Site
City
Turnhout
Country
Belgium
Facility Name
205.235.0428 Boehringer Ingelheim Investigational Site
City
Yvoir
Country
Belgium
Facility Name
205.235.510 Servico de Pneumologia
City
Florianópolis - SC
Country
Brazil
Facility Name
205.235.508
City
Juiz de Fora - MG
Country
Brazil
Facility Name
205.235.501
City
Porto Alegre - RS
Country
Brazil
Facility Name
205.235.503
City
Porto Alegre - RS
Country
Brazil
Facility Name
205.235.506
City
Porto Alegre - RS
Country
Brazil
Facility Name
205.235.507 Depto.de Medicina Interna-Servico de pneumologia
City
Porto Alegre - RS
Country
Brazil
Facility Name
205.235.502
City
Rio de Janeiro - RJ
Country
Brazil
Facility Name
205.235.505 Dep.Medicina Especializada (DEMESP)
City
Rio de Janeiro - RJ
Country
Brazil
Facility Name
205.235.511 Departamento de Pneumologia
City
Salvador - BA
Country
Brazil
Facility Name
205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar
City
Santo André - SP
Country
Brazil
Facility Name
205.235.512
City
São Paulo - SP
Country
Brazil
Facility Name
205.235.513
City
São Paulo - SP
Country
Brazil
Facility Name
205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina
City
São Paulo - SP
Country
Brazil
Facility Name
205.235.515 Lar Escola São Francisco / Setor de Pneumologia
City
São Paulo - SP
Country
Brazil
Facility Name
205.235.0712 Boehringer Ingelheim Investigational Site
City
Benesov
Country
Czech Republic
Facility Name
205.235.0711 Boehringer Ingelheim Investigational Site
City
Beroun
Country
Czech Republic
Facility Name
205.235.0718 Clinic of Functional Diagnostics and Rehabilitation
City
Brno
Country
Czech Republic
Facility Name
205.235.0725 University Hospital Brno
City
Brno
Country
Czech Republic
Facility Name
205.235.0720 Office of Pulmonology and Respiratory Diseases
City
Cesky Tesin
Country
Czech Republic
Facility Name
205.235.0717 Pulmonary Clinic
City
Hradec Kralove
Country
Czech Republic
Facility Name
205.235.0705 Boehringer Ingelheim Investigational Site
City
Jablonec nad Nisou
Country
Czech Republic
Facility Name
205.235.0726 Private Office of Pulmonary Diseases
City
Jaromer
Country
Czech Republic
Facility Name
205.235.0722 Hospital Kromeriz
City
Kromeriz
Country
Czech Republic
Facility Name
205.235.0724 District Hospital Kyjov
City
Kyjov
Country
Czech Republic
Facility Name
205.235.0704 Boehringer Ingelheim Investigational Site
City
Lovosice
Country
Czech Republic
Facility Name
205.235.0702 Boehringer Ingelheim Investigational Site
City
Marianske Lazne
Country
Czech Republic
Facility Name
205.235.0701 Boehringer Ingelheim Investigational Site
City
Plzen
Country
Czech Republic
Facility Name
205.235.0703 Boehringer Ingelheim Investigational Site
City
Plzen
Country
Czech Republic
Facility Name
205.235.0710 Boehringer Ingelheim Investigational Site
City
Prague 5
Country
Czech Republic
Facility Name
205.235.0706 Boehringer Ingelheim Investigational Site
City
Praha 4
Country
Czech Republic
Facility Name
205.235.0709 Boehringer Ingelheim Investigational Site
City
Praha 4
Country
Czech Republic
Facility Name
205.235.0708 Boehringer Ingelheim Investigational Site
City
Praha 5 - Nove Butovice
Country
Czech Republic
Facility Name
205.235.0715 Boehringer Ingelheim Investigational Site
City
Praha 5
Country
Czech Republic
Facility Name
205.235.0707 Boehringer Ingelheim Investigational Site
City
Praha 8
Country
Czech Republic
Facility Name
205.235.0723 Office of Pulmonary and Respiratory Diseases
City
Prerov
Country
Czech Republic
Facility Name
205.235.0721 Office of Pulmonary Diseases
City
Pribor
Country
Czech Republic
Facility Name
205.235.0713 Boehringer Ingelheim Investigational Site
City
Strakonice
Country
Czech Republic
Facility Name
205.235.0714 Boehringer Ingelheim Investigational Site
City
Tabor
Country
Czech Republic
Facility Name
205.235.0719 Office of Pulmonology and Respiratory Diseases
City
Usti nad Orlici
Country
Czech Republic
Facility Name
205.235.0716 Boehringer Ingelheim Investigational Site
City
Znojmo
Country
Czech Republic
Facility Name
205.235.0826 Boehringer Ingelheim Investigational Site
City
Aalborg SV
Country
Denmark
Facility Name
205.235.0804 Boehringer Ingelheim Investigational Site
City
Aalborg
Country
Denmark
Facility Name
205.235.0803 Boehringer Ingelheim Investigational Site
City
Aarhus
Country
Denmark
Facility Name
205.235.0828 Boehringer Ingelheim Investigational Site
City
Copenhagen K
Country
Denmark
Facility Name
205.235.0802 Boehringer Ingelheim Investigational Site
City
Copenhagen NV
Country
Denmark
Facility Name
205.235.0831 Boehringer Ingelheim Investigational Site
City
Copenhagen
Country
Denmark
Facility Name
205.235.0821 Boehringer Ingelheim Investigational Site
City
Frederikshavn
Country
Denmark
Facility Name
205.235.0832 Boehringer Ingelheim Investigational Site
City
Frederikssund
Country
Denmark
Facility Name
205.235.0807 Boehringer Ingelheim Investigational Site
City
Fåborg
Country
Denmark
Facility Name
205.235.0805 Boehringer Ingelheim Investigational Site
City
Hellerup
Country
Denmark
Facility Name
205.235.0835 Boehringer Ingelheim Investigational Site
City
Hellerup
Country
Denmark
Facility Name
205.235.0816 Boehringer Ingelheim Investigational Site
City
Helsingor
Country
Denmark
Facility Name
205.235.0811 Boehringer Ingelheim Investigational Site
City
Hillerød
Country
Denmark
Facility Name
205.235.0834 Boehringer Ingelheim Investigational Site
City
Hobro
Country
Denmark
Facility Name
205.235.0806 Boehringer Ingelheim Investigational Site
City
Holbæk
Country
Denmark
Facility Name
205.235.0814 Boehringer Ingelheim Investigational Site
City
Holstebro
Country
Denmark
Facility Name
205.235.0801 Boehringer Ingelheim Investigational Site
City
Hvidovre
Country
Denmark
Facility Name
205.235.0833 Boehringer Ingelheim Investigational Site
City
Kalundborg
Country
Denmark
Facility Name
205.235.0830 Boehringer Ingelheim Investigational Site
City
Kolding
Country
Denmark
Facility Name
205.235.0819 Boehringer Ingelheim Investigational Site
City
Nykobing F.
Country
Denmark
Facility Name
205.235.0810 Boehringer Ingelheim Investigational Site
City
Næstved
Country
Denmark
Facility Name
205.235.0809 Boehringer Ingelheim Investigational Site
City
Odense C
Country
Denmark
Facility Name
205.235.0815 Boehringer Ingelheim Investigational Site
City
Randers
Country
Denmark
Facility Name
205.235.0824 Boehringer Ingelheim Investigational Site
City
Silkeborg
Country
Denmark
Facility Name
205.235.0813 Boehringer Ingelheim Investigational Site
City
Skive
Country
Denmark
Facility Name
205.235.0822 Boehringer Ingelheim Investigational Site
City
Skive
Country
Denmark
Facility Name
205.235.0820 Boehringer Ingelheim Investigational Site
City
Slagelse
Country
Denmark
Facility Name
205.235.0808 Boehringer Ingelheim Investigational Site
City
Svendborg
Country
Denmark
Facility Name
205.235.0827 Boehringer Ingelheim Investigational Site
City
Værløse
Country
Denmark
Facility Name
205.235.0903 Boehringer Ingelheim Investigational Site
City
Helsinki
Country
Finland
Facility Name
205.235.0901 Boehringer Ingelheim Investigational Site
City
Jyväskylä
Country
Finland
Facility Name
205.235.0905 Boehringer Ingelheim Investigational Site
City
Kotka
Country
Finland
Facility Name
205.235.0904 Boehringer Ingelheim Investigational Site
City
Lahti
Country
Finland
Facility Name
205.235.0902 Boehringer Ingelheim Investigational Site
City
Pori
Country
Finland
Facility Name
205.235.1004 Clinique Toulouse Lautrec
City
Albi cedex 9
Country
France
Facility Name
205.235.1007 Cabinet Médical
City
Albi
Country
France
Facility Name
205.235.1015 Centre Hospitalier
City
Barbezieux St Hilaire
Country
France
Facility Name
205.235.1012 Cabinet Médical
City
Bourges
Country
France
Facility Name
205.235.1024 Cabinet Médical
City
Chamalières
Country
France
Facility Name
205.235.1006 Centre Hospitalier de Chauny
City
Chauny cedex
Country
France
Facility Name
205.235.1005 Polyclinique
City
Cholet
Country
France
Facility Name
205.235.1013 Cabinet Médical
City
La Teste
Country
France
Facility Name
205.235.1020 Cabinet Médical
City
Marseille
Country
France
Facility Name
205.235.1023 Cabinet Médical
City
Montauban
Country
France
Facility Name
205.235.1025 Centre Médical Erdre Saint Augustin
City
Nantes
Country
France
Facility Name
205.235.1002 Cabinet médical
City
Nice
Country
France
Facility Name
205.235.1001 Hôpital Bichat
City
Paris
Country
France
Facility Name
205.235.1016 Cabinet Médical
City
Provins
Country
France
Facility Name
205.235.1019 Cabinet Médical
City
Strasbourg
Country
France
Facility Name
205.235.1009 Centre Hospitalier de Bigorre
City
Tarbes cedex 9
Country
France
Facility Name
205.235.1021 Clinique Pasteur
City
Toulouse
Country
France
Facility Name
205.235.1113 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
205.235.1114 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
205.235.1103 Boehringer Ingelheim Investigational Site
City
Brake
Country
Germany
Facility Name
205.235.1105 Boehringer Ingelheim Investigational Site
City
Braunschweig
Country
Germany
Facility Name
205.235.1104 Boehringer Ingelheim Investigational Site
City
Bruchsal
Country
Germany
Facility Name
205.235.1115 Boehringer Ingelheim Investigational Site
City
Hannover
Country
Germany
Facility Name
205.235.1109 Boehringer Ingelheim Investigational Site
City
Kaufbeuren
Country
Germany
Facility Name
205.235.1108 Boehringer Ingelheim Investigational Site
City
Lörrach
Country
Germany
Facility Name
205.235.1102 Boehringer Ingelheim Investigational Site
City
Lübeck
Country
Germany
Facility Name
205.235.1106 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
205.235.1110 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
205.235.1101 Boehringer Ingelheim Investigational Site
City
Ulm
Country
Germany
Facility Name
205.235.1107 Boehringer Ingelheim Investigational Site
City
Weyhe
Country
Germany
Facility Name
205.235.1112 Boehringer Ingelheim Investigational Site
City
Wiesloch
Country
Germany
Facility Name
205.235.1202 8th Pulmonology Clinic "Sotiria" Athens Chest Hospital
City
Athens
Country
Greece
Facility Name
205.235.1203 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
205.235.1201 Boehringer Ingelheim Investigational Site
City
Heraklion
Country
Greece
Facility Name
205.235.1211 Boehringer Ingelheim Investigational Site
City
Kavala
Country
Greece
Facility Name
205.235.1204 Boehringer Ingelheim Investigational Site
City
Larissa
Country
Greece
Facility Name
205.235.1209 Boehringer Ingelheim Investigational Site
City
Patra
Country
Greece
Facility Name
205.235.1210 Boehringer Ingelheim Investigational Site
City
Patra
Country
Greece
Facility Name
205.235.1205 Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
205.235.1206 Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
205.235.1207 Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
205.235.1401 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
205.235.1403 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
205.235.1402 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
205.235.1404 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
205.235.1303 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
205.235.1308 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
205.235.1309 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
205.235.1310 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
205.235.1311 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
205.235.1318 Boehringer Ingelheim Investigational Site
City
Debrecen
Country
Hungary
Facility Name
205.235.1314 Boehringer Ingelheim Investigational Site
City
Deszk
Country
Hungary
Facility Name
205.235.1306 Boehringer Ingelheim Investigational Site
City
Erd
Country
Hungary
Facility Name
205.235.1315 Boehringer Ingelheim Investigational Site
City
Farkasgyepü
Country
Hungary
Facility Name
205.235.1320 Boehringer Ingelheim Investigational Site
City
Gyula
Country
Hungary
Facility Name
205.235.1307 Boehringer Ingelheim Investigational Site
City
Kiskunhalas
Country
Hungary
Facility Name
205.235.1304 Boehringer Ingelheim Investigational Site
City
Miskolc
Country
Hungary
Facility Name
205.235.1317 Boehringer Ingelheim Investigational Site
City
Mosonmagyarovar
Country
Hungary
Facility Name
205.235.1301 Boehringer Ingelheim Investigational Site
City
Pecs
Country
Hungary
Facility Name
205.235.1313 Boehringer Ingelheim Investigational Site
City
Solymar
Country
Hungary
Facility Name
205.235.1305 Boehringer Ingelheim Investigational Site
City
Sopron
Country
Hungary
Facility Name
205.235.1319 Boehringer Ingelheim Investigational Site
City
Szombathely
Country
Hungary
Facility Name
205.235.1302 Boehringer Ingelheim Investigational Site
City
Tatabanya
Country
Hungary
Facility Name
205.235.1316 Boehringer Ingelheim Investigational Site
City
Törökbalint
Country
Hungary
Facility Name
205.235.1312 Boehringer Ingelheim Investigational Site
City
Veszprem
Country
Hungary
Facility Name
205.235.1505 Boehringer Ingelheim Investigational Site
City
Dublin 15
Country
Ireland
Facility Name
205.235.1503 Boehringer Ingelheim Investigational Site
City
Dublin 4
Country
Ireland
Facility Name
205.235.1501 Boehringer Ingelheim Investigational Site
City
Dublin 9
Country
Ireland
Facility Name
205.235.1631 A. O. SS. Antonio e Biagio e Arrigo
City
Alessandria
Country
Italy
Facility Name
205.235.1613 A. O. S. Giuseppe Moscati
City
Avellino
Country
Italy
Facility Name
205.235.1618 Ospedale Bellaria
City
Bologna
Country
Italy
Facility Name
205.235.1649 Ospedale di Circolo di Busto Arsizio
City
Busto Arsizio (VA)
Country
Italy
Facility Name
205.235.1635 P. O. Roberto Binaghi
City
Cagliari
Country
Italy
Facility Name
205.235.1623 A. O. di Carrara
City
Carrara (Massa)
Country
Italy
Facility Name
205.235.1645 Ospedale Civile "Zappatoni"
City
CASSANO D'ADDA (Milano)
Country
Italy
Facility Name
205.235.1617 Ospedale S. Camillo De Lellis
City
Chieti
Country
Italy
Facility Name
205.235.1612 A. O. S. Antonio Abate
City
Erice (Trapani)
Country
Italy
Facility Name
205.235.1622 A. O. S. Anna
City
Ferrara
Country
Italy
Facility Name
205.235.1646 A. O. di Careggi
City
Firenze
Country
Italy
Facility Name
205.235.1647 A. O. Careggi
City
Firenze
Country
Italy
Facility Name
205.235.1615 Ospedale S. Martino
City
Genova
Country
Italy
Facility Name
205.235.1603 P. O. di Gubbio
City
Gubbio (Perugia)
Country
Italy
Facility Name
205.235.1619 A. O. Fratelli Crobu
City
Iglesias (Cagliari)
Country
Italy
Facility Name
205.235.1648 Ospedale "S. Maria di Collemaggio"
City
L'Aquila
Country
Italy
Facility Name
205.235.1624 Ospedale di Macerata
City
Macerata
Country
Italy
Facility Name
205.235.1634 P. O. Luigi Sacco
City
Milano
Country
Italy
Facility Name
205.235.1639 Ospedale Maggiore
City
Modica (Ragusa)
Country
Italy
Facility Name
205.235.1629 A. O. S. Luigi Gonzaga
City
Orbassano (Torino)
Country
Italy
Facility Name
205.235.1604 P. O. R. Silvestrini
City
Perugia
Country
Italy
Facility Name
205.235.1601 Presidio Ospedaliero di Cisanello
City
Pisa
Country
Italy
Facility Name
205.235.1643 A. O. Santa Maria degli Angeli
City
Pordenone
Country
Italy
Facility Name
205.235.1614 Ospedale Misericordia e Dolce
City
Prato
Country
Italy
Facility Name
205.235.1607 Università degli Studi di Sassari
City
Sassari
Country
Italy
Facility Name
205.235.1608 ASL 1 di Sassari
City
Sassari
Country
Italy
Facility Name
205.235.1606 ASL 4 di Terni
City
Terni
Country
Italy
Facility Name
205.235.1632 ASL 4 - Distretto 2
City
Torino
Country
Italy
Facility Name
205.235.1633 A. O. Umberto I
City
Torrette di Ancona (Ancona)
Country
Italy
Facility Name
205.235.1640 P. O. Cà Foncello
City
Treviso
Country
Italy
Facility Name
205.235.1602 Ospedale di Voghera
City
Voghera (Pavia)
Country
Italy
Facility Name
205.235.1706 Juntendo University Hospital
City
Bunkyo-ku, Tokyo
Country
Japan
Facility Name
205.235.1705 Kameda Medical Center
City
Kamogawa, Chiba
Country
Japan
Facility Name
205.235.1713 Komaki City Hospital
City
Komaki, Aichi
Country
Japan
Facility Name
205.235.1712 Kurume University Hospital
City
Kurume, Fukuoka
Country
Japan
Facility Name
205.235.1708 Shinshu University
City
Matsumoto, Nagano
Country
Japan
Facility Name
205.235.1702 Iwate Medical University Hospital
City
Morioka, Iwate
Country
Japan
Facility Name
205.235.1710 Osaka City University Hospital
City
Osaka, Osaka
Country
Japan
Facility Name
205.235.1711 Kinki University Hospital
City
Osakasayama, Osaka
Country
Japan
Facility Name
205.235.1701 Hokkaido University
City
Sapporo, Hokkaido
Country
Japan
Facility Name
205.235.1703 Tohoku University Hospital
City
Sendai, Miyagi
Country
Japan
Facility Name
205.235.1709 Tosei General Hospital
City
Seto, Aichi
Country
Japan
Facility Name
205.235.1704 Hiraka General Hospital
City
Yokote, Akita
Country
Japan
Facility Name
205.235.1801 Boehringer Ingelheim Investigational Site
City
Kaunas
Country
Lithuania
Facility Name
205.235.1802 Boehringer Ingelheim Investigational Site
City
Kaunas
Country
Lithuania
Facility Name
205.235.1803 Boehringer Ingelheim Investigational Site
City
Vilnius
Country
Lithuania
Facility Name
205.235.1901 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
205.235.1902 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
205.235.1903 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
205.235.2005
City
Ciudad de Mexico
Country
Mexico
Facility Name
205.235.2006 Tlalpan 4000, Pabellón 5, EPOC
City
Ciudad de Mexico
Country
Mexico
Facility Name
205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B.
City
Col. Mitras Centro, Monterrey, N.L.
Country
Mexico
Facility Name
205.235.2002
City
Guadalajara, Jal.
Country
Mexico
Facility Name
205.235.2009
City
Puebla
Country
Mexico
Facility Name
205.235.2010 Depto. De Ivestigación
City
Toluca
Country
Mexico
Facility Name
205.235.2003
City
Zapopan, jalisco
Country
Mexico
Facility Name
205.235.2110 Poli Longziekten
City
Almelo
Country
Netherlands
Facility Name
205.235.2105 Lokatie De Lichtenberg
City
Amersfoort
Country
Netherlands
Facility Name
205.235.2107 Poli Longziekten
City
Delft
Country
Netherlands
Facility Name
205.235.2106 Lokatie Dordwijk
City
Dordrecht
Country
Netherlands
Facility Name
205.235.2104 Poli longziekten
City
Eindhoven
Country
Netherlands
Facility Name
205.235.2102 Martini Ziekenhuis Groningen
City
Groningen
Country
Netherlands
Facility Name
205.235.2112 Poli Longziekten
City
Harderwijk
Country
Netherlands
Facility Name
205.235.2115 Poli Longziekten
City
Heerenveen
Country
Netherlands
Facility Name
205.235.2101 Atrium medisch centrum
City
Heerlen
Country
Netherlands
Facility Name
205.235.2114 Poli Longziekten
City
Hengelo
Country
Netherlands
Facility Name
205.235.2108 Poli Longziekten
City
Leeuwarden
Country
Netherlands
Facility Name
205.235.2109 Poli Longziekten
City
Rotterdam
Country
Netherlands
Facility Name
205.235.2111 Antonius Ziekenhuis
City
Sneek
Country
Netherlands
Facility Name
205.235.0211 Boehringer Ingelheim Investigational Site
City
Auckland
Country
New Zealand
Facility Name
205.235.0212 Boehringer Ingelheim Investigational Site
City
Christchurch, New Zealand
Country
New Zealand
Facility Name
205.235.2202 Boehringer Ingelheim Investigational Site
City
Arendal
Country
Norway
Facility Name
205.235.2201 Boehringer Ingelheim Investigational Site
City
Fredrikstad
Country
Norway
Facility Name
205.235.2205 Boehringer Ingelheim Investigational Site
City
Sandvika
Country
Norway
Facility Name
205.235.2204 Boehringer Ingelheim Investigational Site
City
Straume
Country
Norway
Facility Name
205.235.2301 Philippine General Hospital
City
Manila
Country
Philippines
Facility Name
205.235.2305 University of Santo Tomas Hospital
City
Manila
Country
Philippines
Facility Name
205.235.2302 Philippine Heart Center
City
Quezon City
Country
Philippines
Facility Name
205.235.2303 Veterans Memorial Medical Center
City
Quezon City
Country
Philippines
Facility Name
205.235.2304 Lung Center of the Philippines
City
Quezon City
Country
Philippines
Facility Name
205.235.2410 Boehringer Ingelheim Investigational Site
City
Gdansk
Country
Poland
Facility Name
205.235.2407 Boehringer Ingelheim Investigational Site
City
Katowice
Country
Poland
Facility Name
205.235.2408 Boehringer Ingelheim Investigational Site
City
Krakow
Country
Poland
Facility Name
205.235.2405 Boehringer Ingelheim Investigational Site
City
Lodz
Country
Poland
Facility Name
205.235.2409 Boehringer Ingelheim Investigational Site
City
Lodz
Country
Poland
Facility Name
205.235.2401 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
205.235.2402 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
205.235.2403 Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
205.235.2404 Boehringer Ingelheim Investigational Site
City
Wroclaw
Country
Poland
Facility Name
205.235.2406 Boehringer Ingelheim Investigational Site
City
Zabrze
Country
Poland
Facility Name
205.235.2504 Centro Hospitalar de Coimbra
City
Coimbra
Country
Portugal
Facility Name
205.235.2503 Hospital Pulido Valente
City
Lisboa
Country
Portugal
Facility Name
205.235.2505 Hospital de Santa Marta
City
Lisboa
Country
Portugal
Facility Name
205.235.2501 Hospital de São João
City
Porto
Country
Portugal
Facility Name
205.235.2502 Centro Hospitalar de Vila Nova de Gaia
City
Vila Nova de Gaia
Country
Portugal
Facility Name
205.235.2601 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
205.235.2602 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
205.235.2603 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
205.235.2605 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
205.235.2604 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
205.235.1904 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
205.235.1905 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
205.235.1906 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
205.235.2701 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
205.235.2702 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
205.235.2703 Boehringer Ingelheim Investigational Site
City
Martin
Country
Slovakia
Facility Name
205.235.2704 Boehringer Ingelheim Investigational Site
City
Poprad
Country
Slovakia
Facility Name
205.235.2705 Boehringer Ingelheim Investigational Site
City
Topolcany
Country
Slovakia
Facility Name
205.235.2801 Boehringer Ingelheim Investigational Site
City
Golnik
Country
Slovenia
Facility Name
205.235.2802 Boehringer Ingelheim Investigational Site
City
Golnik
Country
Slovenia
Facility Name
205.235.2805 Boehringer Ingelheim Investigational Site
City
Kamnik
Country
Slovenia
Facility Name
205.235.2803 Boehringer Ingelheim Investigational Site
City
Ljubljana
Country
Slovenia
Facility Name
205.235.2804 Boehringer Ingelheim Investigational Site
City
Topolsica
Country
Slovenia
Facility Name
205.235.2908
City
Bloemfontein
Country
South Africa
Facility Name
205.235.2910
City
Cape Town
Country
South Africa
Facility Name
205.235.2912
City
Cape Town
Country
South Africa
Facility Name
205.235.2904
City
Durban
Country
South Africa
Facility Name
205.235.2911
City
Durban
Country
South Africa
Facility Name
205.235.2902
City
George
Country
South Africa
Facility Name
205.235.2905
City
Paarl
Country
South Africa
Facility Name
205.235.2901 Boehringer Ingelheim Investigational Site
City
Pretoria
Country
South Africa
Facility Name
205.235.2906
City
Somerset West
Country
South Africa
Facility Name
205.235.2903
City
Vanderbijlpark
Country
South Africa
Facility Name
205.235.2909
City
Welkom
Country
South Africa
Facility Name
205.235.3014 Complejo Hospitalario Juan Canalejo
City
A Coruña
Country
Spain
Facility Name
205.235.3026 Hospital General Universitario de Alicante
City
Alicante
Country
Spain
Facility Name
205.235.3011 Complejo Hospitalario Infanta Cristina
City
Badajoz
Country
Spain
Facility Name
205.235.3006 Hospital Germans Trias i Pujol
City
Badalona (Barcelona)
Country
Spain
Facility Name
205.235.3022 Hospital de Cruces
City
Barakaldo (Bilbao)
Country
Spain
Facility Name
205.235.3003 Hospital Clínic i Provincial de Barcelona
City
Barcelona
Country
Spain
Facility Name
205.235.3008 Hospital Vall d'Hebrón
City
Barcelona
Country
Spain
Facility Name
205.235.3023 Hospital Dr. Josep Trueta
City
Girona
Country
Spain
Facility Name
205.235.3004 Hospital General Universitario de Guadalajara
City
Guadalajara
Country
Spain
Facility Name
205.235.3005 Hospital General San Jorge de Huesca
City
Huesca
Country
Spain
Facility Name
205.235.3021 Hospital de Jerez de la Frontera
City
Jerez de la Frontera
Country
Spain
Facility Name
205.235.3010 Hospital Severo Ochoa
City
Leganés, Madrid
Country
Spain
Facility Name
205.235.3009 Hospital Clínico San Carlos
City
Madrid
Country
Spain
Facility Name
205.235.3013 Clínica Puerta de Hierro
City
Madrid
Country
Spain
Facility Name
205.235.3017 Hospital Ramón y Cajal
City
Madrid
Country
Spain
Facility Name
205.235.3020 Hospital Universitario La Paz
City
Madrid
Country
Spain
Facility Name
205.235.3028 Hospital Universitario de la Princesa
City
Madrid
Country
Spain
Facility Name
205.235.3031 Hospital Gregorio Marañón
City
Madrid
Country
Spain
Facility Name
205.235.3036 Hospital 12 de Octubre
City
Madrid
Country
Spain
Facility Name
205.235.3033 Hospital General Carlos Haya
City
Málaga
Country
Spain
Facility Name
205.235.3027 Complejo Asistencial Son Dureta
City
Palma de Mallorca
Country
Spain
Facility Name
205.235.3024 Hospital de Montecelo
City
Pontevedra
Country
Spain
Facility Name
205.235.3016 Hospital Universitari de Sant Joan
City
Reus (Tarragona)
Country
Spain
Facility Name
205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell
City
Sabadell (Barcelona)
Country
Spain
Facility Name
205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria
City
Santa Cruz de Tenerife
Country
Spain
Facility Name
205.235.3039 Hospital Universitario Marqués de Valdecilla
City
Santander
Country
Spain
Facility Name
205.235.3019 Hospital Vírgen de la Macarena
City
Sevilla
Country
Spain
Facility Name
205.235.3035 Hospital Universitario Vírgen del Rocío
City
Sevilla
Country
Spain
Facility Name
205.235.3001 Hospital Mutua Terrassa
City
Terrassa (Barcelona)
Country
Spain
Facility Name
205.235.3002 Hospital Clínico Universitario de Valencia
City
Valencia
Country
Spain
Facility Name
205.235.3025 Hospital Universitario Dr. Peset
City
Valencia
Country
Spain
Facility Name
205.235.3032 Hospital Arnau de Vilanova
City
Valencia
Country
Spain
Facility Name
205.235.3034 Hospital La Fe
City
Valencia
Country
Spain
Facility Name
205.235.3018 Complejo Hospitalario Xeral - Cíes
City
Vigo
Country
Spain
Facility Name
205.235.3030 Hospital Miguel Servet
City
Zaragoza
Country
Spain
Facility Name
205.235.3038 Hospital Clínico Lozano Blesa
City
Zaragoza
Country
Spain
Facility Name
205.235.3202 Boehringer Ingelheim Investigational Site
City
Basel
Country
Switzerland
Facility Name
205.235.3203 Universitätsspital Basel
City
Basel
Country
Switzerland
Facility Name
205.235.3204 Boehringer Ingelheim Investigational Site
City
Faltigberg
Country
Switzerland
Facility Name
205.235.3205 Boehringer Ingelheim Investigational Site
City
Lugano
Country
Switzerland
Facility Name
205.235.3206 Boehringer Ingelheim Investigational Site
City
Montana
Country
Switzerland
Facility Name
205.235.3208 Boehringer Ingelheim Investigational Site
City
Winterthur
Country
Switzerland
Facility Name
205.235.3201 Boehringer Ingelheim Investigational Site
City
Zürich
Country
Switzerland
Facility Name
205.235.3301 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
205.235.3302 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
205.235.3303 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
205.235.3402 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
205.235.3403 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
205.235.3404 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
205.235.3401 Boehringer Ingelheim Investigational Site
City
Chiang Mai
Country
Thailand
Facility Name
205.235.3405 Boehringer Ingelheim Investigational Site
City
Khon Kaen
Country
Thailand
Facility Name
205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi
City
Adana
Country
Turkey
Facility Name
205.235.3506 Hacettepe Tip Fakultesi
City
Ankara
Country
Turkey
Facility Name
205.235.3507 Ankara SSK Diskapi Egitim Hastanesi
City
Ankara
Country
Turkey
Facility Name
205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi
City
Ankara
Country
Turkey
Facility Name
205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye
City
Erzurum
Country
Turkey
Facility Name
205.235.3511 Osmangazi Universitesi Tip Fakültesi
City
Eskisehir
Country
Turkey
Facility Name
205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi
City
Istanbul
Country
Turkey
Facility Name
205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi
City
Istanbul
Country
Turkey
Facility Name
205.235.3503 Tophanelioglu Cad. No: 13/15
City
Istanbul
Country
Turkey
Facility Name
205.235.3504 Cevizli E5 Karayolu
City
Istanbul
Country
Turkey
Facility Name
205.235.3505 Istanbul Universitesi Tip Fakültesi
City
Istanbul
Country
Turkey
Facility Name
205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD
City
Izmir
Country
Turkey
Facility Name
205.235.3615 Boehringer Ingelheim Investigational Site
City
Aberdeen
Country
United Kingdom
Facility Name
205.235.3611 Boehringer Ingelheim Investigational Site
City
Chertsey
Country
United Kingdom
Facility Name
205.235.3613 Boehringer Ingelheim Investigational Site
City
Chesterfield
Country
United Kingdom
Facility Name
205.235.3608 Boehringer Ingelheim Investigational Site
City
Cottingham, Hull
Country
United Kingdom
Facility Name
205.235.3605 Boehringer Ingelheim Investigational Site
City
Exeter
Country
United Kingdom
Facility Name
205.235.3602 Boehringer Ingelheim Investigational Site
City
Glasgow
Country
United Kingdom
Facility Name
205.235.3610 Boehringer Ingelheim Investigational Site
City
Leeds
Country
United Kingdom
Facility Name
205.235.3607 Boehringer Ingelheim Investigational Site
City
Leicester
Country
United Kingdom
Facility Name
205.235.3604 Boehringer Ingelheim Investigational Site
City
Middleton
Country
United Kingdom
Facility Name
205.235.3612 Boehringer Ingelheim Investigational Site
City
Nottingham
Country
United Kingdom
Facility Name
205.235.3616 Boehringer Ingelheim Investigational Site
City
Paisley
Country
United Kingdom
Facility Name
205.235.3614 Boehringer Ingelheim Investigational Site
City
Penarth
Country
United Kingdom
Facility Name
205.235.3603 Boehringer Ingelheim Investigational Site
City
Plymouth
Country
United Kingdom
Facility Name
205.235.3609 Boehringer Ingelheim Investigational Site
City
Sheffield
Country
United Kingdom
Facility Name
205.235.3601 Boehringer Ingelheim Investigational Site
City
Solihull, Birmingham
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
32646424
Citation
Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Gronke L, Voss F, Martinez FJ. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 9;21(1):177. doi: 10.1186/s12931-020-01431-y.
Results Reference
derived
PubMed Identifier
30290801
Citation
Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT(R) trial. Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.
Results Reference
derived
PubMed Identifier
27141828
Citation
Celli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin DP. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT(R) trial. Respir Res. 2016 May 4;17(1):48. doi: 10.1186/s12931-016-0361-4.
Results Reference
derived
PubMed Identifier
25326750
Citation
Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014 Oct 18;14:163. doi: 10.1186/1471-2466-14-163.
Results Reference
derived
PubMed Identifier
25175805
Citation
Tashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res. 2014 Aug 31;15(1):102. doi: 10.1186/s12931-014-0102-5.
Results Reference
derived
PubMed Identifier
23714653
Citation
Janssens W, Liu Y, Liu D, Kesten S, Tashkin DP, Celli BR, Decramer M. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT(R)). Respir Med. 2013 Sep;107(9):1409-16. doi: 10.1016/j.rmed.2013.04.015. Epub 2013 May 25.
Results Reference
derived
PubMed Identifier
22432932
Citation
Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 >/= 60% participating in the UPLIFT(R) trial. COPD. 2012 Jun;9(3):289-96. doi: 10.3109/15412555.2012.656211. Epub 2012 Mar 20.
Results Reference
derived
PubMed Identifier
21955733
Citation
Kesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res. 2011 Sep 28;12(1):129. doi: 10.1186/1465-9921-12-129.
Results Reference
derived
PubMed Identifier
20418083
Citation
Tashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010 Oct;104(10):1495-504. doi: 10.1016/j.rmed.2010.03.033. Epub 2010 Apr 24.
Results Reference
derived
PubMed Identifier
20185426
Citation
Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.
Results Reference
derived
PubMed Identifier
19716598
Citation
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.
Results Reference
derived
PubMed Identifier
18836213
Citation
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.235_U08-3718-04-DS.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.235_Literature.pdf
Description
Related Info

Learn more about this trial

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

We'll reach out to this number within 24 hrs